You are here

Wegovy

Novo seeks a cardiovascular boost

Novo seeks a cardiovascular boost

EP Vantage

Flag link:

This Could Be Novo Nordisk's Next Big Weight-Loss Product

This Could Be Novo Nordisk's Next Big Weight-Loss Product

Motley Fool

Flag link:

Noom to offer prescriptions for weight-loss drugs

Noom to offer prescriptions for weight-loss drugs

Yahoo Finance

Flag link:

Novo Nordisk pauses Wegovy marketing projects to dampen demand

Novo Nordisk pauses Wegovy marketing projects to dampen demand

Fierce Pharma

DTC advertising

Flag link:

‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs

‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs

Stat

Flag link:

Amid high demand, Novo Nordisk temporarily throttles US supply of low-dose Wegovy

Amid high demand, Novo Nordisk temporarily throttles US supply of low-dose Wegovy

Fierce Pharma

Flag link:

In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy

In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy

Fierce Pharma

clinical trials

Flag link:

With Wegovy supply unfettered, Novo Nordisk ratchets up its 2023 growth forecast

With Wegovy supply unfettered, Novo Nordisk ratchets up its 2023 growth forecast

Fierce Pharma

Flag link:

Diabesity drugs and their free ‘contract sales force’

Diabesity drugs and their free ‘contract sales force’

Medical Marketing and Media

Flag link:

CHMP gives thumbs-up for Wegovy use in adolescents, along with nine new drug recommendations

CHMP gives thumbs-up for Wegovy use in adolescents, along with nine new drug recommendations

Endpoints

TG Therapeutics

Bristol Myers Squibb

Flag link:

Covering new weight loss drugs could strain Medicare, policy experts warn

Covering new weight loss drugs could strain Medicare, policy experts warn

Stat

Flag link:

Novo Nordisk notches big GLP-1 sales amid rebounding supplies, but cautions on future 'periodic constraints'

Novo Nordisk notches big GLP-1 sales amid rebounding supplies, but cautions on future 'periodic constraints'

Endpoints

Flag link:

Novo Nordisk to go slow on Wegovy marketing after getting supply issues in check

Novo Nordisk to go slow on Wegovy marketing after getting supply issues in check

Medical Marketing and Media

pharma marketing

Flag link:

‘Diabesity’ marketing set to swell as Novo preps relaunch of weight-loss drug

‘Diabesity’ marketing set to swell as Novo preps relaunch of weight-loss drug

Medical Marketing and Media

pharma marketing

Flag link:

Looming obesity drug rivalry not a concern for Novo CEO

Looming obesity drug rivalry not a concern for Novo CEO

Reuters

Flag link:

Decades-old law keeping older adults from trying new weight loss therapies - and companies are paying millions to try to get it changed

Decades-old law keeping older adults from trying new weight loss therapies - and companies are paying millions to try to get it changed

Marketwatch

Flag link:

Amid Wegovy's supply woes, Novo Nordisk sees surging demand for its original obesity drug Saxenda

Amid Wegovy's supply woes, Novo Nordisk sees surging demand for its original obesity drug Saxenda

Fierce Pharma

drug manufacturing

Flag link:

Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis

Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis

Endpoints

Flag link:

Novo's Wegovy supply rebound on track for later this year as demand stays strong

Novo's Wegovy supply rebound on track for later this year as demand stays strong

Fierce Pharma

Flag link:

Lilly's tirzepatide clears high bar set by Novo's Wegovy in obesity

Lilly's tirzepatide clears high bar set by Novo's Wegovy in obesity

Fierce Biotech

Flag link:

Pages